21780-59-6Relevant academic research and scientific papers
COMPOUNDS AND METHODS FOR TREATMENT OF CANCER BY INHIBITING ATG4B AND BLOCKING AUTOPHAGY
-
Page/Page column 32; 60, (2017/03/14)
ATG4B inhibitor compounds, compositions that include the compounds, and methods for using the compounds and compositions in the treatment of cancer by inhibiting ATG4B and/or blocking autophagy.
Structure-based generation of a new class of potent Cdk4 inhibitors: New de novo design strategy and library design
Honma,Hayashi,Aoyama,Hashimoto,Machida,Fukasawa,Iwama,Ikeura,Ikuta,Suzuki-Takahashi,Iwasawa,Hayama,Nishimura,Morishima
, p. 4615 - 4627 (2007/10/03)
As a first step in structure-based design of highly selective and potent Cdk4 inhibitors, we performed structure-based generation of a novel series of Cdk4 inhibitors. A Cdk4 homology model was constructed according to X-ray analysis of an activated form of Cdk2. Using this model, we applied a new de novo design strategy which combined the de novo design program LEGEND with our in-house structure selection supporting system SEEDS to generate new scaffold candidates. In this way, four classes of scaffold candidates including diarylurea were identified. By constructing diarylurea informer libraries based on the structural requirements of Cdk inhibitors in the ATP binding pocket of the Cdk4 model, we were able to identify a potent Cdk4 inhibitor N-(9-oxo-9H-fluoren-4-yl)-N′-pyridin-2-ylurea 15 (IC50 = 0.10 μM), together with preliminary SAR. We performed a docking study between 15 and the Cdk4 model and selected a reasonable binding mode which is consistent with the SAR. Further modification based on the proposed binding mode provided a more potent compound, N-[(9bR)-5-oxo2,3,5,9b-tetrahydro-1H-pyrrolo[2,1-a]isoindol-9-yl]-N′ -pyridin-2-ylurea 26a (IC50 = 0.042 μM), X-ray analysis of which was accomplished by the soaking method. The predicted binding mode of 15 in Cdk4 was validated by X-ray analysis of the Cdk2-26a complex.
